Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg
Status:
Completed
Trial end date:
2017-10-24
Target enrollment:
Participant gender:
Summary
To investigate safety and efficacy on Japanese subjects treated with nelarabine injection for
intravenous use in clinical settings of the following diseases:
1. T-cell acute lymphocytic leukemia (T-ALL)
2. T-cell lymphoblastic lymphoma (T-LBL) Also, "any adverse events involving neurological
disorder, hypotension, and blood disorder and their details" are to be investigated as
an item of particular concern. In addition, subject outcome (alive or dead) at one year
after the start of treatment will also be investigated.